EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of its lead asset, EP395 (glasmacinal), as an oral treatment for chronic obstructive pulmonary disease (COPD). The published data includes findings from both clinical and preclinical studies. A clinical study conducted in collaboration with the Fraunhofer […]
The post EpiEndo publishes new data supporting glasmacinal’s potential in COPD appeared first on Pharmafile.
